` BGBIO (Bergenbio ASA) vs Oslo OBX Comparison - Alpha Spread

BGBIO
vs
Oslo OBX

Over the past 12 months, BGBIO has underperformed Oslo OBX, delivering a return of -73% compared to the Oslo OBX's 16% growth.

Stocks Performance
BGBIO vs Oslo OBX

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BGBIO vs Oslo OBX

Loading
BGBIO
Oslo OBX
Difference

Performance By Year
BGBIO vs Oslo OBX

Loading
BGBIO
Oslo OBX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Bergenbio ASA vs Peers

Oslo OBX
BGBIO
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Bergenbio ASA
Glance View

Market Cap
342.7m NOK
Industry
Biotechnology

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

BGBIO Intrinsic Value
0.203 NOK
Overvaluation 98%
Intrinsic Value
Price
B
Back to Top